Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel, well-tolerated, oral treatments of cancer and other serious illnesses.
Cantex is led by Stephen Marcus, M.D., Neil Flanzraich and Juan Rodriguez; seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience.
Azeliragon is a safe, once-daily oral medication in Phase 2/3 development that targets glioblastoma, metastatic brain tumors, pancreatic cancer, breast cancer, and prevention of acute kidney injury in hospitalized patients with pneumonia.
March 2024 – Cantex Pharmaceuticals announced that Stephen Marcus, M.D., Chief Executive Officer, will be an expert speaker at 5th Annual Glioblastoma Drug Development Summit, delivering a podium presentation titled, ““Delving into a Clinical Update on Azeliragon for GBM – Implementable Lessons for Small Molecule Success.”
February 2024 – Cantex Pharmaceuticals announced that Stephen Marcus, M.D., Chief Executive Officer, is participating in the BIO CEO & Investor Conference and is conducting one-on-one meetings with registered investors, showcasing the Company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
September 2023 – Cantex Pharmaceuticals and Michigan Medicine announced the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial to evaluate the safety and efficacy of Cantex’s azeliragon in decreasing the incidence of acute kidney injury and other life-threatening complications in patients hospitalized for COVID-19.